Back to search

Peptide record

TPDB09540

Antibacterial Anticancer Antifungal Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09540
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, and Antifungipept, with an available 3D structural model.
Sequence
HLRRINKLLTRIGLYRHAFG
Physicochemical Analysis
C111H184N38O24
DCEQMPSWV
RL
2434.92
12.41
7
0
9
+5
1.63
-0.290
122.00
Mammalian: 3.5 hour Yeast: 10 min E.coli: >10 hour
1490
61.19
3
Residue Composition
number
1
A
4
R
1
N
0
D
0
C
0
E
0
Q
2
G
2
H
2
I
4
L
1
K
0
M
1
F
0
P
0
S
1
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 1 R: 4 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 2 I: 2 L: 4 K: 1 M: 0 F: 1 P: 0 S: 0 T: 1 W: 0 Y: 1 V: 0
Chemical Descriptors
20
C111H184N38O24
2434.92
12.41
+5
1.63
-0.290
Evidence Records 20 records
Evidence 1 Activity

Activity

MIC
Antibacterial
32-256 µg/mL

Target

Staphylococcus aureus MRSA

Source & Reference

NA

Other

Active against bacteria S. aureus MRSA (MIC 32-256 ug/ml), K. pneumoniae (MIC 64-128 ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P.
Evidence 2 Activity

Activity

MIC
Antibacterial
64-128 µg/mL

Target

Klebsiella pneumoniae

Source & Reference

NA

Other

Active against bacteria S. aureus MRSA (MIC 32-256 ug/ml), K. pneumoniae (MIC 64-128 ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (32-256 ug/ml), C.coli
Evidence 3 Activity

Activity

MIC
Antibacterial
4-16 µg/mL

Target

A. baumannii 14 clinical strains

Source & Reference

NA

Other

ive against bacteria S. aureus MRSA (MIC 32-256 ug/ml), K. pneumoniae (MIC 64-128 ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (32-256 ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. c
Evidence 4 Activity

Activity

MIC
Antibacterial
>128 µg/mL

Target

C.coli

Source & Reference

NA

Other

ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (32-256 ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml),
Evidence 5 Activity

Activity

MIC
Antibacterial
64 µg/mL

Target

Escherichia coli K12

Source & Reference

NA

Other

/ml), P. aeruginosa (32-256 ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 u
Evidence 6 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

S. typhimurium

Source & Reference

NA

Other

ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: in
Evidence 7 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Enterococcus faecalis

Source & Reference

NA

Other

C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm fo
Evidence 8 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

L. monocytogenes

Source & Reference

NA

Other

E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm formation and disrupted bacterial biof
Evidence 9 Activity

Activity

MIC
Antifungal
32-256 µg/mL

Target

Staphylococcus aureus MRSA

Source & Reference

Antifungipept

Other

Active against bacteria S. aureus MRSA (MIC 32-256 ug/ml), K. pneumoniae (MIC 64-128 ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P.
Evidence 10 Activity

Activity

MIC
Antifungal
64-128 µg/mL

Target

Klebsiella pneumoniae

Source & Reference

Antifungipept

Other

Active against bacteria S. aureus MRSA (MIC 32-256 ug/ml), K. pneumoniae (MIC 64-128 ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (32-256 ug/ml), C.coli
Evidence 11 Activity

Activity

MIC
Antifungal
4-16 µg/mL

Target

A. baumannii 14 clinical strains

Source & Reference

Antifungipept

Other

ive against bacteria S. aureus MRSA (MIC 32-256 ug/ml), K. pneumoniae (MIC 64-128 ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (32-256 ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. c
Evidence 12 Activity

Activity

MIC
Antifungal
>128 µg/mL

Target

C.coli

Source & Reference

Antifungipept

Other

ug/ml), A. baumannii 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (32-256 ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml),
Evidence 13 Activity

Activity

MIC
Antifungal
64 µg/mL

Target

Escherichia coli K12

Source & Reference

Antifungipept

Other

/ml), P. aeruginosa (32-256 ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 u
Evidence 14 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

S. typhimurium

Source & Reference

Antifungipept

Other

ug/ml), C.coli (MIC>128 ug/ml), C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: in
Evidence 15 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Enterococcus faecalis

Source & Reference

Antifungipept

Other

C. jejuni (32 ug/ml) or >128, E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm fo
Evidence 16 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

L. monocytogenes

Source & Reference

Antifungipept

Other

E. coli K12 (MIC 64 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm formation and disrupted bacterial biof
Evidence 17 Activity

Activity

20% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
20% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The rumen microbiome: an underexplored resource for novel antimicrobial discovery. | NPJ Biofilms Microbiomes | 2017
Evidence 18 Activity

Activity

25% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
25% Hemolysis | 500 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
The rumen microbiome: an underexplored resource for novel antimicrobial discovery. | NPJ Biofilms Microbiomes | 2017
Evidence 19 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
The rumen microbiome: an underexplored resource for novel antimicrobial discovery. | NPJ Biofilms Microbiomes | 2017
Evidence 20 Activity

Activity

% Hemolysis
Toxicity
20 %
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 20% Hemolysis=500µg/ml Sheep erythrocytes: 25% Hemolysis=500µg/ml | Cytotoxicity: HUVEC: Not active up to 128 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
NPJ Biofilms Microbiomes. 2017 Dec 1 3:33.